Articles in this Issue

  • Endotoxin Test Concerns of Biologics Part II: Developing New Tools

    Kevin L. Williams
    Bacterial Endotoxin Test (BET) users seek ways to overcome low endotoxin recovery (LER) from direct spikes into undiluted biologics. These studies have come about from Chen’s initial observation1 that Control Standard Endotoxin (CSE) spikes, when placed into undiluted biologics, buff ers, and other constituents often cannot be recovered. By changing the endotoxin spike requirement from diluted product to undiluted product, users will unsurprisingly encounter test interference; what is unexpected from Chen’s LER fi nding is that recovery sometimes cannot be improved by dilution. This is indicative of a still undefi ned binding phenomenon.
  • Industry Case Studies: Integration of Biorelevant Dissolution Data with Physiologically-based...

    Filippos Kesisoglou, Ph.D.
    Dissolution experiments have been used for years as a quality control tool for pharmaceutical products. The accompanying dissolution specifications are intended to ensure consistency between formulation batches during development and manufacturing. More recently, increased attention has been placed on biorelevant dissolution. Biorelevant dissolution, defined as dissolution in media designed to mimic the composition of the gastrointestinal fluids [1], allows for study of formulation behavior in an environment that could be considered closer to the in vivo conditions compared to compendial media, especially for BCS II/IV drugs. As such, biorelevant dissolution could be seen as more useful in understanding the clinical implications of any formulation changes.
  • Justification of Incubation Conditions Used for Environmental Monitoring

    Jeanne Moldenhauer
    Recently, a number of different documents have been making statements similar to “incubation conditions and media used must be justified”. Many companies were able to cite USP as a rationale for using two different incubation conditions including 20°C-25°C and 30°C-35°C. However, the most recent revision to USP states: “Time and incubation temperatures are set once the appropriate media have been selected. Typically, for general microbiological growth media such as SCDM, incubation temperatures in the ranges of approximately 20°C–35°C have been used with an incubation time of not less than 72 hours.” [1]. With a 15°C range in temperature, it is not likely that a single study will provide adequate data to justify the incubation conditions use. As such, companies need to generate data to support the incubation conditions utilized.
  • Pharmaceutical Applications of Raman Spectroscopy

    Stuart Farquharson, Ph.D.
    Raman spectroscopy is becoming one of the most popular analytical measurement tools for pharmaceutical applications ranging from verification of raw materials to process monitoring of drug production to quality control of products. Similar to an infrared spectrum, a Raman spectrum consists of a wavelength distribution of peaks corresponding to molecular vibrations specific to the sample being analyzed (see Figure 1B). Chemicals, such as drugs, can be identified by the frequency and quantified by the intensity of the peaks. In practice, a laser is focused into the sample, the inelastic scattered radiation (Raman) is optically collected and directed into a spectrometer, which provides wavelength separation, and a detector converts photon energy to electrical signal intensity. An attractive advantage to this technique is that samples do not have to be extracted or prepared, and the laser can simply be aimed at a sample to perform chemical measurements, which can often be accomplished in a minute or less.
  • Sample Displacement Chromatography for Protein Purification

    Laura Heikaus, Dr. Hartmut Schlüter
    Displacement chromatography (DC) can be advantageous in comparison to gradient chromatography. Parameters favoring DC allow significantly larger sample loads since the binding capacity can be exploited more efficiently
  • Enhancing Microbial Control and Sterility Assurance in Aseptic Processing by Implementing Single-Use...

    Michael Hodgkinson
    The adoption of single-use technologies in drug product manufacturing has introduced many benefits for the pharmaceutical/ biopharmaceutical industry. It has also introduced the need for an entirely new way of thinking for a group of developing subject matter experts to deal with a fresh set of challenges. Many of the advantages of single-use technology have been well-characterized and discussed in literature, including the reduction of cross-contamination risks and cleaning validation program related resources, as well as faster changeover times on the production floor, lower capital investment costs on facility start-ups and less costs associated with routine cleaning and sterilization of product contacting parts.
  • 50th Anniversary of LAL Reagent Development

    Actually, we use all four methods: gel-clot, kinetic turbidimetric, kinetic chromogenic – and the PTS™. These methods are used to test and release incoming raw materials and to evaluate intermediate formulation buff ers that are subsequently used to produce licensed LAL products. Our accessory products also benefi t from the use of these methods prior to release. Finally, we leverage all of these techniques in developing and validating LAL test methods for customer-specifi c products.
  • An Interview With Michael E. Dawson, Ph.D., RAC Director of Regulatory Affairs Associates of...

    Associates of Cape Cod, Inc.’s (ACC) fourth generation tube reader, the Pyros® Kinetix Flex, offers the most sensitive bacterial endotoxin test (BET) available for both turbidimetric and chromogenic kinetic methods. In addition to flexibility of test method, ACC offers a choice of 32, 64 and 96 well readers. All of these readers provide the flexibility to add tubes at any time. Unlike a microplate reader, additional samples can be added after a test has been started.
  • An Interview With Allen L. Burgenson Manager, Regulatory Affairs Lonza Walkersville, Inc.

    The development of the endpoint chromogenic technology was a critical step in the development of the kinetic chromogenic assays that are in regular use today around the world. The discovery was based on determining the sequence of amino acids at the cleavage site of coagulin, the last step in the enzymatic cascade leading to gel clot formulation in the classical gel-clot LAL assay. Once this sequence was known, a peptide could be sequenced that could be attached to a chromophore. When the chromophore was cleaved from the peptide, a yellow color was generated. The amount of color generated by enzymatic cleavage was proportionate to the amount of endotoxin in the sample, and could be measured using a spectrophotometer. Generation of color development, rather than a clot or turbidity, made it easier to test samples that were not colorless.
  • An Interview With Alan Hoffmeister, Foster T. Jordan & John Dubczak of Charles River

    In one word: sensitivity. From blood coagulation systems to cellular signaling systems, there are a number of cascading enzymatic systems whose mechanisms have been elucidated. Among these systems, the horseshoe crab coagulation system, mediated by bacterial endotoxins, is unique. Through its distinct biological amplification facility, it can detect bacterial endotoxin concentrations to less than 1 part per trillion.
  • <<
  • >>